Dr Hari Pujar | Vice President Technical Development and Manufacturing
Moderna Therapeutics

Dr Hari Pujar, Vice President Technical Development and Manufacturing, Moderna Therapeutics

Dr. Hari Pujar is the Vice President of Technical Development and Manufacturing at Moderna Therapeutics, a privately-held RNA therapeutics company.  Previously, he was a Global Product Leader for pediatric and adult vaccine franchises representing over $2B+ in annual revenue in the commercial division of Merck & Co., Inc., with responsibility covering R&D, manufacturing, and commercial strategy.  Earlier, also at Merck, Dr. Pujar managed bioprocess development, external bioprocess R&D, and external cGMP manufacturing of vaccines, novel biologics, and biosimilars, where he contributed to product development from late discovery through commercialization, including global regulatory filings for a number of vaccine and biologics candidates.
He has been active in leadership roles with the American Chemical Society, including serving as the Chair of the Biotechnology Division.  He served as a steering committee member of the EPSRC Innovative Manufacturing Research Center for Bioprocessing and Center for Innovative Manufacturing in Emergent Macromolecular Therapies, both at University College London. He has been adjunt/invited lecturer at University College London, University of Delaware, Johns Hopkins University, Villanova University, Indian Institute of Technology, and Indian Institute of Science.  He has authored numerous peer-reviewed publications and is a co-editor of a book on Vaccine Development and Manufacturing.  He has won the James van Lanen Award of the American Chemical Society and is a Fellow of the American Institute of Medical and Biological Engineering.
He holds a bachelor’s degree in Chemical Engineering from Institute of Chemical Technology, Mumbai, a Ph.D. in Chemical Engineering from the University of Delaware and an MBA in Finance from the Wharton School at the University of Pennsylvania.


DC Co-conference Day 2 April 4 @ 09:00

Chair’s opening remarks

DC Co-conference Day 2 April 4 @ 09:10

mRNA vaccines: A potentially disruptive modality

back to speakers